Literature DB >> 20488304

Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium.

Samuel Sossalla1, Birte Kallmeyer, Stefan Wagner, Marek Mazur, Ulrike Maurer, Karl Toischer, Jan D Schmitto, Ralf Seipelt, Friedrich A Schöndube, Gerd Hasenfuss, Luiz Belardinelli, Lars S Maier.   

Abstract

OBJECTIVES: We investigated changes in Na(+) currents (I(Na)) in permanent (or chronic) atrial fibrillation (AF) and the effects of I(Na) inhibition using ranolazine (Ran) on arrhythmias and contractility in human atrial myocardium.
BACKGROUND: Electrical remodeling during AF is typically associated with alterations in Ca(2+) and K(+) currents. It remains unclear whether I(Na) is also altered.
METHODS: Right atrial appendages from patients with AF (n = 23) and in sinus rhythm (SR) (n = 79) were studied.
RESULTS: Patch-clamp experiments in isolated atrial myocytes showed significantly reduced peak I(Na) density ( approximately 16%) in AF compared with SR, which was accompanied by a 26% lower expression of Nav1.5 (p < 0.05). In contrast, late I(Na) was significantly increased in myocytes from AF atria by approximately 26%. Ran (10 mumol/l) decreased late I(Na) by approximately 60% (p < 0.05) in myocytes from patients with AF but only by approximately 18% (p < 0.05) in myocytes from SR atria. Proarrhythmic activity was elicited in atrial trabeculae exposed to high [Ca(2+)](o) or isoprenaline, which was significantly reversed by Ran (by 83% and 100%, respectively). Increasing pacing rates from 0.5 to 3.0 Hz led to an increase in diastolic tension that could be significantly decreased by Ran in atria from SR and AF patients.
CONCLUSIONS: Na(+) channels may contribute to arrhythmias and contractile remodeling in AF. Inhibition of I(Na) with Ran had antiarrhythmic effects and improved diastolic function. Thus, inhibition of late I(Na) may be a promising new treatment option for patients with atrial rhythm disturbances and diastolic dysfunction. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20488304     DOI: 10.1016/j.jacc.2009.12.055

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  105 in total

Review 1.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

2.  Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation?

Authors:  Joachim R Ehrlich; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

3.  [Heart failure. Excitation-contraction coupling and novel therapeutic options].

Authors:  A G Rokita; C-M Sag; L S Maier
Journal:  Herz       Date:  2011-03       Impact factor: 1.443

Review 4.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

5.  Long-term modulation of Na+ and K+ channels by TGF-β1 in neonatal rat cardiac myocytes.

Authors:  Roberto Ramos-Mondragón; Ana Victoria Vega; Guillermo Avila
Journal:  Pflugers Arch       Date:  2011-01-13       Impact factor: 3.657

Review 6.  Ion Channels in the Heart.

Authors:  Daniel C Bartos; Eleonora Grandi; Crystal M Ripplinger
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

7.  A truncating SCN5A mutation combined with genetic variability causes sick sinus syndrome and early atrial fibrillation.

Authors:  Azza Ziyadeh-Isleem; Jérôme Clatot; Nathalie Neyroud; Pascale Guicheney; Sabine Duchatelet; Estelle Gandjbakhch; Isabelle Denjoy; Françoise Hidden-Lucet; Stéphane Hatem; Isabelle Deschênes; Alain Coulombe
Journal:  Heart Rhythm       Date:  2014-02-25       Impact factor: 6.343

8.  Diabetes increases mortality after myocardial infarction by oxidizing CaMKII.

Authors:  Min Luo; Xiaoqun Guan; Elizabeth D Luczak; Di Lang; William Kutschke; Zhan Gao; Jinying Yang; Patric Glynn; Samuel Sossalla; Paari D Swaminathan; Robert M Weiss; Baoli Yang; Adam G Rokita; Lars S Maier; Igor R Efimov; Thomas J Hund; Mark E Anderson
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

Review 9.  [Diastolic heart failure].

Authors:  R Wachter
Journal:  Internist (Berl)       Date:  2014-06       Impact factor: 0.743

10.  Emerging clinical role of ranolazine in the management of angina.

Authors:  David S Vadnais; Nanette K Wenger
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.